Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 22 2023 - 6:54AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2023
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Directorate Change
22 May 2023 07:05 BST
Non-Executive Board Appointment
AstraZeneca PLC announced today that Anna Manz has been appointed
as a Non-Executive Director and a member of the Audit Committee
with effect from 1 September 2023.
Anna is currently an Executive Director and the Group Chief
Financial Officer of London Stock Exchange Group plc.
Michel Demaré, Chair of AstraZeneca, said "We are delighted to
welcome Anna to the AstraZeneca Board. She brings extensive
cross-sector business skills and knowledge to the Board, having
held international roles in North America and Asia Pacific and
served as an executive and non-executive in large, listed
companies. Anna's significant financial and strategic leadership
experience, including in areas such as risk, treasury and
accounting, will enable her to fully contribute to the work of our
Audit Committee."
Biographical details - Anna Manz
Anna joined London Stock Exchange Group plc in November 2020 as
Chief Financial Officer, ahead of the $27 billion acquisition of
Refinitiv. From 2016 - 2020, she was an Executive Director and the
Chief Financial Officer of Johnson Matthey Plc and led its Finance,
Procurement and IT functions. Prior to joining Johnson Matthey,
Anna spent 17 years at Diageo plc in a number of senior finance
roles, including Chief Strategy Officer and as a member of the
Executive Committee. She brings extensive expertise in accounting,
corporate finance and mergers and acquisitions, as well as
experience of business diversification and
transformation.
Anna has been a Non-Executive Director of ITV plc since 2016 and
has served on its Audit Committee and Remuneration Committee for
most of that period. She will step down as a Non-Executive Director
of ITV at the end of August this year.
Except as set out above, no disclosure obligations arise under
paragraphs (1) to (6) of LR 9.6.13 R of the UK Financial Conduct
Authority's Listing Rules in respect of this
appointment.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
22 May 2023
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Oct 2024 to Nov 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Nov 2023 to Nov 2024
